Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 11 | 2024 | 313 | 2.740 |
Why?
|
| Leukocytes | 5 | 2025 | 205 | 1.690 |
Why?
|
| P-Selectin | 4 | 2020 | 69 | 1.600 |
Why?
|
| Vimentin | 4 | 2024 | 59 | 1.410 |
Why?
|
| Leukapheresis | 3 | 2025 | 14 | 1.270 |
Why?
|
| Microfluidics | 3 | 2025 | 31 | 0.960 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 405 | 0.950 |
Why?
|
| Intravital Microscopy | 2 | 2022 | 20 | 0.880 |
Why?
|
| Neutrophils | 3 | 2021 | 371 | 0.880 |
Why?
|
| Thrombosis | 6 | 2022 | 499 | 0.840 |
Why?
|
| Cannula | 1 | 2024 | 32 | 0.820 |
Why?
|
| Histones | 3 | 2022 | 541 | 0.800 |
Why?
|
| Cell Adhesion | 2 | 2020 | 308 | 0.740 |
Why?
|
| Respiratory Insufficiency | 2 | 2024 | 247 | 0.710 |
Why?
|
| Endothelium, Vascular | 2 | 2018 | 468 | 0.700 |
Why?
|
| Endotoxemia | 2 | 2020 | 54 | 0.700 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2025 | 682 | 0.690 |
Why?
|
| Pneumonia | 1 | 2024 | 341 | 0.630 |
Why?
|
| von Willebrand Diseases | 2 | 2022 | 54 | 0.630 |
Why?
|
| Liver Transplantation | 7 | 2024 | 1147 | 0.630 |
Why?
|
| Platelet Aggregation | 2 | 2024 | 100 | 0.580 |
Why?
|
| Acetaminophen | 2 | 2021 | 100 | 0.580 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 1319 | 0.580 |
Why?
|
| Echocardiography | 2 | 2024 | 1125 | 0.580 |
Why?
|
| Epithelium, Corneal | 3 | 2021 | 175 | 0.500 |
Why?
|
| Corneal Injuries | 2 | 2021 | 36 | 0.470 |
Why?
|
| Receptors, Proteinase-Activated | 1 | 2015 | 2 | 0.470 |
Why?
|
| Antithrombin III | 1 | 2015 | 22 | 0.460 |
Why?
|
| Corneal Keratocytes | 1 | 2015 | 5 | 0.450 |
Why?
|
| End Stage Liver Disease | 4 | 2024 | 193 | 0.430 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 131 | 0.430 |
Why?
|
| Cell Separation | 5 | 2025 | 218 | 0.430 |
Why?
|
| Hepatocytes | 1 | 2015 | 232 | 0.410 |
Why?
|
| Animals | 19 | 2026 | 33912 | 0.410 |
Why?
|
| von Willebrand Factor | 5 | 2022 | 191 | 0.410 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 157 | 0.390 |
Why?
|
| Microcirculation | 3 | 2022 | 104 | 0.380 |
Why?
|
| Serum Albumin | 1 | 2013 | 101 | 0.380 |
Why?
|
| Wound Healing | 2 | 2021 | 490 | 0.360 |
Why?
|
| Lung Transplantation | 3 | 2022 | 363 | 0.350 |
Why?
|
| Critical Care | 3 | 2025 | 686 | 0.350 |
Why?
|
| Endothelium | 2 | 2022 | 59 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 544 | 0.340 |
Why?
|
| Respiration, Artificial | 2 | 2025 | 501 | 0.340 |
Why?
|
| Mice | 14 | 2026 | 18301 | 0.330 |
Why?
|
| Sepsis | 3 | 2022 | 493 | 0.310 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 3 | 2021 | 160 | 0.300 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2020 | 66 | 0.290 |
Why?
|
| Cystic Fibrosis | 2 | 2022 | 268 | 0.290 |
Why?
|
| Humans | 39 | 2026 | 131163 | 0.280 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2021 | 74 | 0.270 |
Why?
|
| Biliary Atresia | 2 | 2023 | 223 | 0.270 |
Why?
|
| Inflammation | 5 | 2022 | 1489 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 4738 | 0.260 |
Why?
|
| Child | 22 | 2025 | 26341 | 0.260 |
Why?
|
| Endothelial Cells | 1 | 2010 | 523 | 0.260 |
Why?
|
| Male | 21 | 2026 | 64957 | 0.250 |
Why?
|
| Benzo(a)pyrene | 1 | 2026 | 28 | 0.240 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2024 | 19 | 0.240 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 514 | 0.240 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 145 | 0.230 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2025 | 91 | 0.220 |
Why?
|
| Cytokines | 2 | 2025 | 1339 | 0.220 |
Why?
|
| Infant | 12 | 2025 | 13352 | 0.220 |
Why?
|
| Venules | 2 | 2022 | 28 | 0.220 |
Why?
|
| Leukocytosis | 1 | 2025 | 46 | 0.220 |
Why?
|
| Child, Preschool | 13 | 2025 | 15110 | 0.220 |
Why?
|
| Leukocyte Count | 1 | 2025 | 246 | 0.210 |
Why?
|
| Liver | 2 | 2022 | 1796 | 0.210 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2024 | 10 | 0.210 |
Why?
|
| Death | 1 | 2025 | 78 | 0.200 |
Why?
|
| Factor XIII Deficiency | 1 | 2024 | 10 | 0.200 |
Why?
|
| Video Games | 1 | 2025 | 96 | 0.200 |
Why?
|
| Blood Component Removal | 1 | 2023 | 35 | 0.200 |
Why?
|
| Macrophages | 2 | 2025 | 667 | 0.200 |
Why?
|
| Female | 18 | 2026 | 70963 | 0.200 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 95 | 0.200 |
Why?
|
| Ferritins | 2 | 2021 | 104 | 0.190 |
Why?
|
| Arginine | 1 | 2025 | 340 | 0.190 |
Why?
|
| Hospital Costs | 1 | 2024 | 188 | 0.190 |
Why?
|
| Hemostatics | 1 | 2022 | 58 | 0.180 |
Why?
|
| Craniocerebral Trauma | 1 | 2024 | 144 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1105 | 0.180 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 215 | 0.180 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2021 | 3 | 0.170 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2021 | 7 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2021 | 3 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 1 | 2025 | 254 | 0.170 |
Why?
|
| CD18 Antigens | 1 | 2021 | 42 | 0.170 |
Why?
|
| Hyperemia | 1 | 2021 | 30 | 0.170 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 903 | 0.170 |
Why?
|
| Cell Degranulation | 1 | 2021 | 27 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2022 | 93 | 0.170 |
Why?
|
| Critical Illness | 6 | 2022 | 630 | 0.170 |
Why?
|
| Vasculitis | 1 | 2021 | 47 | 0.170 |
Why?
|
| Retrospective Studies | 11 | 2024 | 17753 | 0.170 |
Why?
|
| Virus Replication | 1 | 2024 | 608 | 0.170 |
Why?
|
| Mast Cells | 1 | 2021 | 68 | 0.170 |
Why?
|
| Interferometry | 1 | 2020 | 21 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2021 | 186 | 0.160 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 64 | 0.160 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 500 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 154 | 0.160 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 161 | 0.150 |
Why?
|
| Protein Domains | 1 | 2020 | 252 | 0.150 |
Why?
|
| Centrifugation | 3 | 2024 | 19 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2021 | 217 | 0.150 |
Why?
|
| Rats | 1 | 2025 | 3370 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2021 | 212 | 0.140 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 33 | 0.140 |
Why?
|
| Escherichia coli | 1 | 2024 | 991 | 0.140 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 49 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2021 | 327 | 0.130 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2018 | 28 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 587 | 0.130 |
Why?
|
| Plasma Exchange | 1 | 2018 | 86 | 0.130 |
Why?
|
| Coronary Care Units | 1 | 2017 | 34 | 0.130 |
Why?
|
| Fibrin | 3 | 2022 | 65 | 0.130 |
Why?
|
| Transportation of Patients | 1 | 2017 | 51 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2018 | 246 | 0.130 |
Why?
|
| Cornea | 1 | 2021 | 569 | 0.120 |
Why?
|
| Protein Binding | 1 | 2020 | 1652 | 0.120 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 172 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2018 | 223 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 266 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2026 | 4697 | 0.110 |
Why?
|
| Pediatrics | 1 | 2025 | 1252 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 83 | 0.110 |
Why?
|
| Chemokines | 1 | 2015 | 126 | 0.110 |
Why?
|
| Bile Acids and Salts | 2 | 2023 | 262 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2018 | 385 | 0.100 |
Why?
|
| Anemia | 1 | 2018 | 354 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8635 | 0.100 |
Why?
|
| Platelet Function Tests | 1 | 2013 | 37 | 0.100 |
Why?
|
| Cell Movement | 2 | 2021 | 876 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2015 | 767 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 2012 | 102 | 0.090 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2012 | 115 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 196 | 0.080 |
Why?
|
| Blood Cell Count | 1 | 2010 | 65 | 0.080 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 47 | 0.080 |
Why?
|
| Coinfection | 1 | 2012 | 187 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3147 | 0.080 |
Why?
|
| Bile Duct Diseases | 1 | 2010 | 16 | 0.080 |
Why?
|
| Risk Factors | 5 | 2023 | 11074 | 0.080 |
Why?
|
| Adolescent | 7 | 2024 | 20987 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 808 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1224 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 483 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2021 | 3819 | 0.070 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 161 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 571 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 3061 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1591 | 0.060 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2022 | 142 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2012 | 712 | 0.060 |
Why?
|
| Argininosuccinate Synthase | 1 | 2025 | 25 | 0.060 |
Why?
|
| Heart | 1 | 2010 | 650 | 0.060 |
Why?
|
| RAW 264.7 Cells | 1 | 2025 | 49 | 0.060 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2026 | 82 | 0.060 |
Why?
|
| Myocardium | 1 | 2010 | 852 | 0.060 |
Why?
|
| Length of Stay | 2 | 2024 | 1421 | 0.060 |
Why?
|
| Argininosuccinate Lyase | 1 | 2025 | 61 | 0.050 |
Why?
|
| Viral Load | 1 | 2026 | 416 | 0.050 |
Why?
|
| Filtration | 1 | 2024 | 21 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1216 | 0.050 |
Why?
|
| Factor XIII | 1 | 2024 | 13 | 0.050 |
Why?
|
| Citrulline | 1 | 2025 | 128 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2025 | 299 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2022 | 79 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2022 | 53 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 156 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2022 | 43 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2025 | 175 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2025 | 471 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2022 | 44 | 0.040 |
Why?
|
| Incidence | 2 | 2021 | 3360 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2022 | 170 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2021 | 12936 | 0.040 |
Why?
|
| Adult | 3 | 2023 | 31282 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2021 | 68 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2025 | 506 | 0.040 |
Why?
|
| Collagen | 1 | 2022 | 273 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 305 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 115 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 105 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 407 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2021 | 190 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 208 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 450 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 285 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 544 | 0.040 |
Why?
|
| Regeneration | 1 | 2021 | 230 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2021 | 253 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 57 | 0.030 |
Why?
|
| Lung | 1 | 2026 | 1535 | 0.030 |
Why?
|
| Cold Ischemia | 1 | 2018 | 29 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2018 | 90 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2025 | 1050 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2018 | 64 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1295 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1483 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 6196 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2018 | 166 | 0.030 |
Why?
|
| Operative Time | 1 | 2018 | 201 | 0.030 |
Why?
|
| Doxycycline | 1 | 2018 | 112 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2017 | 103 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 97 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2017 | 73 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 322 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 361 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 506 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1882 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1118 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 552 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 361 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1071 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 398 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1378 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1410 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3829 | 0.020 |
Why?
|
| Methylmalonic Acid | 1 | 2012 | 15 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1240 | 0.020 |
Why?
|
| Medical Audit | 1 | 2012 | 98 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2200 | 0.020 |
Why?
|
| Vasoplegia | 1 | 2012 | 22 | 0.020 |
Why?
|
| Phenotype | 2 | 2012 | 4497 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3359 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4886 | 0.020 |
Why?
|
| Dicarbethoxydihydrocollidine | 1 | 2010 | 3 | 0.020 |
Why?
|
| Glycogen | 1 | 2010 | 50 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 42 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 6459 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 10103 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 222 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5063 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 294 | 0.020 |
Why?
|
| Fatigue | 1 | 2010 | 191 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 429 | 0.020 |
Why?
|
| United States | 1 | 2024 | 12072 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 289 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2010 | 377 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 5196 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2596 | 0.010 |
Why?
|
| Gene Expression | 1 | 2010 | 1481 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 3711 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4686 | 0.010 |
Why?
|